February 5, 2008. By Gordon Gibb.
Kenilworth, NJ The long-awaited, and long-delayed release of the ENHANCE study on the effects and efficacy of the cholesterol drug Vytorin (Zocor combined with Zetia) may have done more than raise the ire of doctors and the medical community: it also may have ticked off investors of Schering-Plough, one of the two manufacturers involved in Vytorin. The delay may translate into a breach of ERISA-mandated fiduciary duty regarding employees participating in a Schering-Plough pension plan.
Read [
Schering-Plough: Dragging Heels on Vytorin Study, a Breach of ERISA? ]
